^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunosuppressant

    Related drugs:
    1d
    Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis. (PubMed, J Immunother Cancer)
    Nearly half of patients developing ir-hepatitis had an inadequate response to steroids and needed MMF as a secondary immunosuppressant. Patients with mixed DILI were more likely to respond to steroids, while alcohol consumption was associated with inadequate steroid response. Immune analyses showed high T cell infiltration in the liver among patients with ir-hepatitis.
    Journal • Checkpoint inhibition
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • NCAM1 (Neural cell adhesion molecule 1) • FOXP3 (Forkhead Box P3)
    1d
    A Blood Stem Cell Transplant for Sickle Cell Disease (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • pentostatin
    3d
    HAP2HCT: TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, St. Jude Children's Research Hospital | N=140 --> 69 | Trial completion date: Aug 2025 --> Jun 2026
    Enrollment change • Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • WT1 (WT1 Transcription Factor) • CREBBP (CREB binding protein) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • HOXA9 (Homeobox A9) • NUP214 (Nucleoporin 214) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KAT6A (Lysine Acetyltransferase 6A) • KDM5A (Lysine Demethylase 5A) • DEK (DEK Proto-Oncogene) • AFDN (Afadin, Adherens Junction Formation Factor) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    FLT3-ITD mutation
    |
    cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    3d
    A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (clinicaltrials.gov)
    P2, N=24, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • bortezomib • cyclophosphamide • dexamethasone • fludarabine IV
    7d
    Classic hodgkin lymphoma associated with Epstein-Barr virus reactivation during vedolizumab therapy for ulcerative colitis. (PubMed, Clin J Gastroenterol)
    Azathioprine was administered eight years prior but was discontinued after a short period due to liver dysfunction. Laparoscopic total proctocolectomy was performed, and the surgical specimen contained Reed-Sternberg cells positive for CD20, CD30, PD-L1, and EBV-encoded RNA, establishing EBV-associated cHL. Although the development of cHL is likely multifactorial, clinicians should be aware that EBV-associated intestinal cHL may develop in patients with UC receiving vedolizumab when tumor-like ulcers or mural thickening are encountered.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    CD20 positive
    |
    Entyvio (vedolizumab)
    8d
    TRIUMPH: TReatment for ImmUne Mediated PathopHysiology (clinicaltrials.gov)
    P2, N=163, Recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Trial completion date: May 2027 --> Feb 2027 | Trial primary completion date: Apr 2027 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    methylprednisolone sodium succinate
    8d
    Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New trial
    8d
    WAVE T1D: A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (clinicaltrials.gov)
    P1/2, N=120, Not yet recruiting, City of Hope Medical Center | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    11d
    SUNFLOWER: A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (clinicaltrials.gov)
    P3, N=245, Not yet recruiting, AstraZeneca
    New P3 trial
    14d
    WAVE T1D: A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, City of Hope Medical Center | Not yet recruiting --> Withdrawn | N=120 --> 0
    Enrollment change • Trial withdrawal
    15d
    TN40A: Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Trial completion date: Dec 2029 --> May 2030 | Initiation date: Dec 2025 --> Apr 2026
    Trial completion date • Trial initiation date
    15d
    Stem Cell Transplantation in Crohn's Disease (clinicaltrials.gov)
    P1/2, N=15, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • mesna • Neupogen (filgrastim) • methylprednisolone sodium succinate